Scientists searching for the origins of COVID-19 have zeroed in on a short list of animals that possibly helped spread it to ...

Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the fourth quarter of 2024. Voyager is eligible to receive ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...

On September 9, Planned Parenthood of the Pacific Southwest reopened the Imperial Valley Homan Health Center a year after a ...

GTX-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aSAH patients to address significant unmet medical needs. The unique ...

Pioneers Memorial Healthcare District announced on Monday "the departure" of CEO Christopher R. Bjornberg. "After thorough discussion and consideration, it was decided by the Board of Directors to ...

Bjornberg. “After thorough discussion and consideration, it was decided by the Board of Directors to move forward with this ...

The results further demonstrate the potential for TILT-123 as an intravenous therapy. The data presented covers the results of a Phase I clinical cohort of TILT-123 monotherapy for the treatment of ...

GTX-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aSAH patients to address significant unmet medical needs. The unique ...

Attorneys representing both living and deceased patients of an Oregon hospital filed a $303 million lawsuit against the ...